Retatrutide is a synthetic triple agonist targeting the GIP, GLP-1 and glucagon (GCGR) receptors, a frontier incretin-based research compound.
It is studied in metabolic research for combined GIP, GLP-1 and glucagon receptor signalling and its effects on energy expenditure and glucose-handling pathways in laboratory models.
Supplied as a lyophilised powder, batch-identified and cross-referenced to a third-party HPLC Certificate of Analysis (COA). In keeping with the GenoPept standard — analytical purity over presentation — it ships in clinical packaging with discreet, tracked UK dispatch.
Research use only. Intended strictly for in-vitro laboratory and scientific research. Not for human or veterinary use.




Reviews
There are no reviews yet.